Shailja Kaul, MD
Endocrinology, Diabetes & Metabolism · Langhorne, PANPI 1780841270
Payments from drug & device makers
Across 452 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$904
- AstraZeneca$887
- Lilly USA, LLC$793
- Mannkind Corporation$443
- Corcept Therapeutics$380
- plus $4K from 41 others
What the payments were for
- Food & beverage$8,60598%
- Education$651%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,789 in reported general payments places this provider in the 70th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 377 | $605,158 |
| MounjaroTirzepatide | 227 | $285,566 |
| TrulicityDulaglutide | 161 | $253,928 |
| FarxigaDapagliflozin Propanediol | 168 | $201,845 |
| JardianceEmpagliflozin | 137 | $162,610 |
| JanuviaSitagliptin Phosphate | 95 | $108,566 |
| Tresiba Flextouch U-100Insulin Degludec | 105 | $70,277 |
| Novolog FlexpenInsulin Aspart | 130 | $38,798 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $38,768 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $37,808 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $34,660 |
| ProliaDenosumab | 19 | $32,653 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 85 | $29,712 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $28,121 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 62 | $27,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $904 | $617,428409 claims |
| Lilly USA, LLCMounjaro, Trulicity | $793 | $539,494388 claims |
| AstraZenecaFarxiga | $887 | $201,845168 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $362 | $200,539176 claims |
| MerckJanuvia, Janumet, Janumet Xr | $102 | $153,629138 claims |
| AmgenProlia | $1,177 | $32,65319 claims |
| BayerKerendia | $86 | $11,60013 claims |
| AbbVieSynthroid | $45 | $7,98483 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $32 | $7,614476 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Langhorne
- Alan SchorrLanghorne$287K
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.